CIP
NTLA icon

Chartwell Investment Partners’s Intellia Therapeutics NTLA Stock Holding History

Chartwell Investment Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,239
Closed -$974K – 436
2021
Q4 		$974K Sell
8,239
-158
-2% -$19.8K 0.03% 384
2021
Q3 		$1.13M Buy
8,397
+3,112
+59% +$471K 0.04% 366
2021
Q2 		$856K Buy
+5,285
New +$412K 0.03% 386

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chartwell Investment Partners's NTLA Position: Q1 2022 in Review

Chartwell Investment Partners sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 8,239 shares — an estimated $974K sold.

Chartwell Investment Partners first reported a position in NTLA in Q2 2021 and held it in 3 quarters. The position peaked at $1.13M in Q3 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Chartwell Investment Partners reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 8,239 Intellia Therapeutics shares in Q1 2022, an estimated $974K.
  • Chartwell Investment Partners first reported a position in Intellia Therapeutics in Q2 2021 and held it in 3 quarters.
  • Chartwell Investment Partners's Intellia Therapeutics position peaked at $1.13M in Q3 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Chartwell Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.